#VisualAbstract: Belantamab Mafodotin, Pomalidomide, and Dexamethasone Improve Outcomes in Multiple Myeloma
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Tag: multiple myeloma
Minimal Residual Disease negativity after Autologous Hematopoietic Cell Transplantation with lenalidomide maintenance predicts better long-term outcomes in myeloma
1. Achieving Minimal Residual Disease (MRD) negativity at baseline before lenalidomide maintenance, and at one-year post Auto-HCT (AutoHCT) predicts increased ...
Subcutaneous daratumumab with VRd improves progression-free survival in multiple myeloma
1. Adding subcutaneous daratumumab to VRd (bortezomib, lenalidomide, and dexamethasone) induction/consolidation, and lenalidomide maintenance therapy improves progression-free survival in eligible ...
#VisualAbstract: Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed ...
#VisualAbstract: Cilta-cel or Standard Care in Lenalidomide Refractory Multiple Myeloma
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
#VisualAbstract: Carfilzomib, dexamethasone, and lenalidomide superior to lenalidomide monotherapy for multiple myeloma
Click to read this study in The Lancet Oncology.
LCAR-B38M CAR-T cell therapy promising at 4-year follow-up for treatment of refractory multiple myeloma
1. At a 4-year follow-up for relapsed or refractory multiple myeloma (RRMM) patients treated with LCAR-B38M CAR-T cell therapy, 37.8% ...
